Mesa Laboratories Inc. (NASDAQ: MLAB) presented an overview of its business at the J.P. Morgan 2026 Healthcare Conference. The company reported fiscal year 2025 revenues of $241 million, with a diversified portfolio across clinical genomics, biopharmaceutical development, calibration solutions, and sterilization & disinfection control. Mesa highlighted its continued organic growth, with a five-year compound annual growth rate $(CAGR)$ of 15.4% in revenues and an increase in high-growth vertical exposure from 50% to 69% over the past five years. The company also noted strong operating leverage, with a fiscal year 2025 gross profit margin of 62.6% and an adjusted operating income margin of 23.5%. Mesa emphasized ongoing commercial execution and expansion in regulated markets through both organic growth and strategic M&A activities. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mesa Laboratories Inc. published the original content used to generate this news brief on January 14, 2026, and is solely responsible for the information contained therein.